Bell Potter names the ASX healthcare shares to buy in 2023

These could be the healthcare shares to buy in 2023…

| More on:
Five healthcare workers standing together and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're interested in adding some healthcare sector exposure to your portfolio, then it could be worth taking a look at what Bell Potter is recommending.

It has named its top picks in the healthcare sector for 2023 and the two ASX healthcare shares named below are on the list.

Here's what the broker is saying about these shares:

PolyNovo Ltd (ASX: PNV)

This medical device company is an ASX healthcare share to buy according to Bell Potter. Its analysts currently have a buy rating and $2.30 price target on its shares. This compares to the latest PolyNovo share price of $2.04.

Its analysts believe a recent capital raising leaves PolyNovo well-placed for growth. It commented:

The key offering of Polynovo is the proprietary biodegradable temporising matrix (BTM) that is utilised in the management of complex wounds and severe burns. The recent $33m capital raising in November 2022 provides the growth platform to facilitate expansion of the US and global sales team with key markets in Asia & Canada being targeted. Product launch within Hong Kong and India has already taken place during 1H23 whilst entry into Japan/ China is planned through a distributor model. These new operating segments increase the addressable market especially in regions with a significant healthcare burden of burns and complex/trauma wounds.

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX healthcare share to buy could be this radiopharmaceutical company. Its analysts currently have a buy rating and $9.00 price target on its shares. This is notably higher than the current Telix share price of $6.97.

The broker is expecting Telix's Illuccix product to generate material revenue in 2023. It also remains optimistic on its clinical trials. The broker explained:

We retain TLX as a key pick following very strong execution of its US business plan over recent months. Revenues from the sale of Illuccix continue to grow each quarter and the product is now expected to generate in excess of $300m in revenues in 2023. In the clinic, TLX 101 has generated positive trial data for the treatment of glioblastoma and TLX 250CDx reported positive data from its pivotal study for the imaging of clear cell renal carcinoma. The product is now expected to become the company's second on market in late calendar year 2023. Telix remains well capitalised with $117m in cash at 30 September 2022 and based on our forecast, is expected to generate its maiden profit in CY2023.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »